The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2021 | Latest news in gastric cancer from ASCO GI
Geoffrey Ku, MD, Memorial Sloan Kettering Cancer Center, New York, NY, explores key updates from the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, including the results of the FIGHT study in esophagogastric cancer, the findings of the use of ZW25, a bispecific antibody in HER2-positive tumors, as well as the approval of trastuzumab deruxtecan, an antibody-drug conjugate in HER2-positive gastric cancer by the FDA based on the results of the DESTINY-Gastric01 study. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
Disclosures
Dr Ku reports Apexigen (consulting), AstraZeneca (research support), BMS (research support, consulting), Daiichi-Sankyo (research support), Merck (research support, consulting), Oncolys (research support), Pieris (research support, consulting), Zymeworks (research support).
